Oculis Holding AG OCS
7.79 USD +0.20 (+2.57%)
Nov 11, 2026, 1:37 PM EST
7.67 Day range 8.03
6.78 52-week range 34.48
- YTD
- -61.02%
- 1 year
- -59.87%
News
globenewswire.com Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline ZUG, Switzerland, November 9, 2026 -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations in neuro-ophthalmology and…
globenewswire.com Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline ZUG, Switzerland, November 9, 2026 -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) ("Oculis"), a global biopharmaceutical company focused on breakthrough innovations in neuro-ophthalmology and…
zacks.com Down 21.1% in 4 Weeks, Here's Why Oculis Holding AG (OCS) Looks Ripe for a Turnaround The heavy selling pressure might have exhausted for Oculis Holding AG (OCS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street…
benzinga.com Guggenheim Maintains Buy on Oculis Holding, Lowers Price Target to $40 Guggenheim analyst Yatin Suneja maintains Oculis Holding (NASDAQ:OCS) with a Buy and lowers the price target from $45 to $40.
benzinga.com Oculis Holding Q3 EPS $(0.37) Beats $(0.49) Estimate, Sales $8.619K Miss $290.000K Estimate Oculis Holding (NASDAQ:OCS) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.49) by 24.49 percent. This is a 5.13 percent increase over losses of…
benzinga.com HC Wainwright & Co. Reiterates Buy on Oculis Holding, Maintains $39 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Oculis Holding (NASDAQ:OCS) with a Buy and maintains $39 price target.
benzinga.com Oculis Says Phase 2 ACUITY Biomarker Data Show Privosegtor Lowered NfL, GFAP Versus Placebo In Optic Neuritis, Strengthening Confidence In PIONEER Registrational Program, Exploring Acute MS Relapses Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placeboLower NfL and GFAP levels provide objective,…- benzinga.com Oculis To Report Topline Results Around Year-End 2026 From First Genotype-Guided Registrational Dry Eye Trial Of Licaminlimab, Now Fully Randomized With 176 Patients, Two-Thirds Carrying Target TNFR1 Variant High-Responder Target Enrichment: 2/3 of the 176 enrolled patients carry the target TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trialsPrecision Medicine Approach…
benzinga.com Apple To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Friday Analysts downgraded XENE, NFLX and MGA, while raising price targets for OCS, INSW, ABEO and STNG.- benzinga.com HC Wainwright & Co. Maintains Buy on Oculis Holding, Raises Price Target to $39 HC Wainwright & Co. analyst Yi Chen maintains Oculis Holding (NASDAQ:OCS) with a Buy and raises the price target from $26 to $39.
benzinga.com JP Morgan Maintains Overweight on Oculis Holding, Lowers Price Target to $20 JP Morgan analyst Tessa Romero maintains Oculis Holding (NASDAQ:OCS) with a Overweight and lowers the price target from $23 to $20.
benzinga.com Oculis Acquires Accure's Privosegtor And ACT-02 Assets In Deal Worth $3.8M Upfront Cash And Up To 2,050,000 Shares Transaction will enhance Oculis’ strategic flexibility and ownership of Privosegtor while driving long-term value creationTransaction consideration includes $3.8 million up-front cash payment at…
benzinga.com Oculis Holding Q2 EPS $(0.20) Beats $(0.48) Estimate, Sales $392.150K Beat $260.000K Estimate Oculis Holding (NASDAQ:OCS) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.48) by 58.33 percent. This is a 64.91 percent increase over losses of…- benzinga.com HC Wainwright & Co. Maintains Buy on Oculis Holding, Maintains $26 Price Target HC Wainwright & Co. analyst Yi Chen maintains Oculis Holding (NASDAQ:OCS) with a Buy and maintains $26 price target.
benzinga.com Oculis To Submit IND For Privosegtor In Acute MS Relapses In Q4 2026, Backed By Positive FDA Pre-IND Guidance And Prior Optic Neuritis Data The FDA Division of Neurology provided positive feedback supporting a regulatory pathway for Privosegtor in acute multiple sclerosis (MS) relapses, addressing a significant unmet medical need The FDA…
benzinga.com Intuitive Surgical, Netflix And Other Big Stocks Moving Lower In Friday’s Pre-Market Session U.S. stock futures lower, Nasdaq 100 down 2%. Intuitive Surgical shares dip 11.3% after Q2 earnings beat estimates. Other stocks also falling in pre-market.
benzinga.com Oculis Announces First Patient Randomized In PREDICT-1 Registrational Trial Of Licaminlimab For Dry Eye Disease PREDICT-1 is the first genotype-based registrational trial in dry eye disease (DED), with the potential of delivering a first-in-class precision medicine treatment in DEDThis FDA-aligned trial…- benzinga.com JP Morgan Maintains Overweight on Oculis Holding, Lowers Price Target to $23 JP Morgan analyst Tessa Romero maintains Oculis Holding (NASDAQ:OCS) with a Overweight and lowers the price target from $42 to $23.
- benzinga.com Baird Maintains Outperform on Oculis Holding, Lowers Price Target to $38 Baird analyst Colleen Kusy maintains Oculis Holding (NASDAQ:OCS) with a Outperform and lowers the price target from $49 to $38.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session - benzinga.com Stifel Maintains Buy on Oculis Holding, Lowers Price Target to $40 Stifel analyst Annabel Samimy maintains Oculis Holding (NASDAQ:OCS) with a Buy and lowers the price target from $50 to $40.
benzinga.com Why Is Oculis Stock Sinking Monday? Oculis (OCS) stock plummets 37% after its Phase 3 DIAMOND trials for diabetic macular edema fail to meet the primary endpoint.- benzinga.com Guggenheim Maintains Buy on Oculis Holding, Lowers Price Target to $45 Guggenheim analyst Yatin Suneja maintains Oculis Holding (NASDAQ:OCS) with a Buy and lowers the price target from $75 to $45.
benzinga.com Dell Technologies To Gain Nearly 79%? Here Are 10 Analyst Calls Investors Should Know Wall Street analysts updated views on notable stocks. See changes on analyst ratings page. Price targets raised/cut, ratings maintained/changed.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session - benzinga.com Needham Maintains Buy on Oculis Holding, Lowers Price Target to $38 Needham analyst Serge Belanger maintains Oculis Holding (NASDAQ:OCS) with a Buy and lowers the price target from $46 to $38.
- benzinga.com HC Wainwright & Co. Maintains Buy on Oculis Holding, Lowers Price Target to $26 HC Wainwright & Co. analyst Yi Chen maintains Oculis Holding (NASDAQ:OCS) with a Buy and lowers the price target from $47 to $26.
benzinga.com Why Taylor Morrison Home Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket Taylor Morrison Home soared 23.28% to $72.12 in pre-market trading after Berkshire Hathaway announced to acquire the homebuilder.- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Oculis Holding Reports Topline Results From Phase 3 DIAMOND-1 And DIAMOND-2 Trials Of OCS-01 Eye Drops In Patients With DME; Primary BCVA Endpoint Not Met The primary endpoint of mean change in best corrected visual acuity (BCVA) from baseline to week 52 in both Phase 3 trials was not met The secondary endpoint of retinal thickness showed a substantial…
- benzinga.com Guggenheim Initiates Coverage On Oculis Holding with Buy Rating, Announces Price Target of $75 Guggenheim analyst Yatin Suneja initiates coverage on Oculis Holding (NASDAQ:OCS) with a Buy rating and announces Price Target of $75.
- benzinga.com JP Morgan Maintains Overweight on Oculis Holding, Raises Price Target to $42 JP Morgan analyst Tessa Romero maintains Oculis Holding (NASDAQ:OCS) with a Overweight and raises the price target from $38 to $42.
- benzinga.com Needham Maintains Buy on Oculis Holding, Raises Price Target to $46 Needham analyst Serge Belanger maintains Oculis Holding (NASDAQ:OCS) with a Buy and raises the price target from $40 to $46.
benzinga.com HC Wainwright & Co. Maintains Buy on Oculis Holding, Raises Price Target to $47 HC Wainwright & Co. analyst Yi Chen maintains Oculis Holding (NASDAQ:OCS) with a Buy and raises the price target from $44 to $47.- benzinga.com Oculis Holding Q1 EPS $(0.63) Misses $(0.49) Estimate, Sales $266.845K Miss $320.000K Estimate Oculis Holding (NASDAQ:OCS) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.49) by 26.53 percent. This is a 19.48 percent increase over losses of…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Oculis Holding, Maintains $44 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Oculis Holding (NASDAQ:OCS) with a Buy and maintains $44 price target.
- benzinga.com Oculis Completes Final Patient Visits In Both Phase 3 DIAMOND Trials For OCS-01 Diabetic Macular Edema Eye Drop Treatment Last patient visits for both OCS-01 Phase 3 DIAMOND trials (total 800+ patients) are complete, with topline results expected in June 2026A non-invasive topical treatment for diabetic macular edema…
- benzinga.com Oculis Receives European Medicines Agency PRIME Designation For Privosegtor In Optic Neuritis, Accelerating PIONEER Registrational Program Across Three Global Trials PRIME designation follows recent Breakthrough Therapy designation from the U.S. FDA, underscoring the importance and urgency of addressing optic neuritis, a serious condition that can have negative…
- benzinga.com Stifel Maintains Buy on Oculis Holding, Raises Price Target to $50 Stifel analyst Annabel Samimy maintains Oculis Holding (NASDAQ:OCS) with a Buy and raises the price target from $40 to $50.
- benzinga.com HC Wainwright & Co. Maintains Buy on Oculis Holding, Raises Price Target to $44 HC Wainwright & Co. analyst Yi Chen maintains Oculis Holding (NASDAQ:OCS) with a Buy and raises the price target from $42 to $44.
- benzinga.com Needham Maintains Buy on Oculis Holding, Raises Price Target to $40 Needham analyst Serge Belanger maintains Oculis Holding (NASDAQ:OCS) with a Buy and raises the price target from $36 to $40.
- benzinga.com CORRECTION: Oculis Holding Q4 EPS $(0.53) Misses $(0.43) Estimate, Sales $514.161K Beat $270.000K Estimate Oculis Holding (NASDAQ:OCS) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.43) by 23.26 percent. This is a 30.26 percent increase over losses of…
- benzinga.com Oculis To Present Late-Stage Pipeline Progress Including Breakthrough Therapy And Phase 3 Milestones At 2026 J.P. Morgan Healthcare Conference Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential market of $7B+ in the U.S. aloneMultiple milestones…
benzinga.com Microchip Technology, Alumis, Terrestrial Energy, Bright Minds Biosciences And Other Big Stocks Moving Higher On Tuesday - benzinga.com Oculis Secures FDA Breakthrough Therapy Designation For Privosegtor In Optic Neuritis As PIONEER Program Targets $7B US Neuroprotective Market Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritisPrivosegtor is advancing in the registrational PIONEER program across 2 key…
- benzinga.com Stifel Maintains Buy on Oculis Holding, Raises Price Target to $40 Stifel analyst Annabel Samimy maintains Oculis Holding (NASDAQ:OCS) with a Buy and raises the price target from $35 to $40.
benzinga.com This AeroVironment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - benzinga.com JP Morgan Initiates Coverage On Oculis Holding with Overweight Rating, Announces Price Target of $38 JP Morgan analyst Tessa Romero initiates coverage on Oculis Holding (NASDAQ:OCS) with a Overweight rating and announces Price Target of $38.
benzinga.com This Linde Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - benzinga.com LifeSci Capital Initiates Coverage On Oculis Holding with Outperform Rating, Announces Price Target of $55 LifeSci Capital initiates coverage on Oculis Holding (NASDAQ:OCS) with a Outperform rating and announces Price Target of $55.